Hydroxychloroquine Reactions 1680, p161 - 2 Dec 2017 Retinal toxicity: 17 case reports In a retrospective study, 17 patients (16 women and one man, aged 34 77 years) were described, who developed retinal toxicity during treatment with hydroxychloroquine [routes, time to reactions onsets and outcomes not stated]. Eight of the 17 patients were diagnosed with systemic lupus erythematosus and the rest were diagnosed with rheumatoid arthritis. All the patients received treatment with hydroxychloroquine at a daily dosage ranged from – – 4.9 9.1 mg/kg for the total duration of 6.7 21.9 years. However, following hydroxychloroquine administration, the visual field testing showed findings that varied from partial or complete ring scotoma sparing central fovea to subtle defects on the pattern deviation plot. The spectral domain optical coherence tomography (SD-OCT) showed thinning of outer nuclear layer or disruption of perifoveal photoreceptor inner segment/outer segment junction. The fundus autofluorescence (FAF) imaging revealed photoreceptor damage (except in one patient) as hyperautofluorescence by accumulated lipofuscin or hypoautofluorescence due to retinal pigment epithelial cell loss. These ophthalmological findings led to the diagnosis of early, moderate or severe retinal toxicity, which was considered to be related with hydroxychloroquine administration. The pattern of the retinal toxicity varied from parafoveal or pericentral to mixed. Author comment: "[Hydroxychloroquine] retinal toxicity is associated with duration of [hydroxychloroquine] use, daily [hydroxychloroquine] dose, and presence of kidney disease." "We found 17 patients (13.8%) with [Hydroxychloroquine] retinal toxicity among 123 patients." Kim J-W, et al. Risk of retinal toxicity in longterm users of hydroxychloroquine. The Journal of Rheumatology 44: 1674-1679, No. 11, Nov 2017. Available from: URL: http://doi.org/10.3899/jrheum.170158 - South Korea 803285479 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial